Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Ischemic Heart Disease

Free Subscription Articles published in JAMA Retrieve available abstracts of 115 articles: HTML format Text format

Single Articles

July 2018
1. WILKINS JT, Lloyd-Jones DM
   USPSTF Recommendations for Assessment of Cardiovascular Risk With Nontraditional Risk Factors: Finding the Right Tests for the Right Patients.
   JAMA. 2018 Jul 10. pii: 2687223. doi: 10.1001/jama.2018.9346.
   PubMed     Text format    
   
   
   
2. CURRY SJ, Krist AH, Owens DK, Barry MJ, et al
   Screening for Peripheral Artery Disease and Cardiovascular Disease Risk Assessment With the Ankle-Brachial Index: US Preventive Services Task Force Recommendation Statement.
   JAMA. 2018;320:177-183.
   PubMed     Text format     Abstract available
   
   
   
3. LIN JS, Evans CV, Johnson E, Redmond N, et al
   Nontraditional Risk Factors in Cardiovascular Disease Risk Assessment: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
   JAMA. 2018 Jul 10. pii: 2687224. doi: 10.1001/jama.2018.4242.
   PubMed     Text format     Abstract available
   
   
   
4. CURRY SJ, Krist AH, Owens DK, Barry MJ, et al
   Risk Assessment for Cardiovascular Disease With Nontraditional Risk Factors: US Preventive Services Task Force Recommendation Statement.
   JAMA. 2018 Jul 10. pii: 2687225. doi: 10.1001/jama.2018.8359.
   PubMed     Text format     Abstract available
   
   
   June 2018
5. SELAK V, Kerr A, Poppe K, Wu B, et al
   Annual Risk of Major Bleeding Among Persons Without Cardiovascular Disease Not Receiving Antiplatelet Therapy.
   JAMA. 2018;319:2507-2520.
   PubMed     Text format     Abstract available
   
   
   
6. JONAS DE, Reddy S, Middleton JC, Barclay C, et al
   Screening for Cardiovascular Disease Risk With Resting or Exercise Electrocardiography: Evidence Report and Systematic Review for the US Preventive Services Task Force.
   JAMA. 2018;319:2315-2328.
   PubMed     Text format     Abstract available
   
   
   
7. CURRY SJ, Krist AH, Owens DK, Barry MJ, et al
   Screening for Cardiovascular Disease Risk With Electrocardiography: US Preventive Services Task Force Recommendation Statement.
   JAMA. 2018;319:2308-2314.
   PubMed     Text format     Abstract available
   
   
   
8. JIN J
   Screening for Cardiovascular Disease Risk With ECG.
   JAMA. 2018;319:2346.
   PubMed     Text format    
   
   
   
9. MCCARTHY CP, Vaduganathan M, Januzzi JL Jr
   Type 2 Myocardial Infarction-Diagnosis, Prognosis, and Treatment.
   JAMA. 2018 Jun 11. pii: 2684931. doi: 10.1001/jama.2018.7125.
   PubMed     Text format    
   
   
   
10. MERCHANT FM, Dickert NW Jr, Howard DH
    Mandatory Shared Decision Making by the Centers for Medicare & Medicaid Services for Cardiovascular Procedures and Other Tests.
    JAMA. 2018 Jun 4. pii: 2683805. doi: 10.1001/jama.2018.6617.
    PubMed     Text format    
    
    
    May 2018
11. BHATT DL
    Percutaneous Coronary Intervention in 2018.
    JAMA. 2018;319:2127-2128.
    PubMed     Text format    
    
    
    
12. ABBASI J
    Another Nail in the Coffin for Fish Oil Supplements.
    JAMA. 2018;319:1851-1852.
    PubMed     Text format    
    
    
    April 2018
13. ZHAO Q, Zhu Y, Xu Z, Cheng Z, et al
    Effect of Ticagrelor Plus Aspirin, Ticagrelor Alone, or Aspirin Alone on Saphenous Vein Graft Patency 1 Year After Coronary Artery Bypass Grafting: A Randomized Clinical Trial.
    JAMA. 2018;319:1677-1686.
    PubMed     Text format     Abstract available
    
    
    
14. ALEXANDER JH
    Ticagrelor Following Coronary Artery Bypass Grafting: For Better Vein Graft Patency or Better Patient Outcomes?
    JAMA. 2018;319:1661-1662.
    PubMed     Text format    
    
    
    
15. NAVARESE EP, Robinson JG, Kowalewski M, Kolodziejczak M, et al
    Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis.
    JAMA. 2018;319:1566-1579.
    PubMed     Text format     Abstract available
    
    
    
16. ABBASI J
    Using Heart Pump Data to Manage Cardiogenic Shock.
    JAMA. 2018;319:1427.
    PubMed     Text format    
    
    
    
17. YU K, Qiu G, Chan KH, Lam KH, et al
    Association of Solid Fuel Use With Risk of Cardiovascular and All-Cause Mortality in Rural China.
    JAMA. 2018;319:1351-1361.
    PubMed     Text format     Abstract available
    
    
    March 2018
18. GUPTA A, Das SR, Pandey A
    beta-Blockers in Myocardial Infarction: Issues With Standard Admission Order Sets.
    JAMA. 2018;319:1269-1270.
    PubMed     Text format    
    
    
    
19. BERWANGER O, Santucci EV, de Barros E Silva PGM, Jesuino IA, et al
    Effect of Loading Dose of Atorvastatin Prior to Planned Percutaneous Coronary Intervention on Major Adverse Cardiovascular Events in Acute Coronary Syndrome: The SECURE-PCI Randomized Clinical Trial.
    JAMA. 2018 Mar 11. pii: 2675023. doi: 10.1001/jama.2018.2444.
    PubMed     Text format     Abstract available
    
    
    
20. NICHOLLS SJ, Psaltis PJ
    Lipid Lowering in Acute Coronary Syndrome: Is Treatment Early Enough?
    JAMA. 2018 Mar 11. pii: 2675022. doi: 10.1001/jama.2018.2426.
    PubMed     Text format    
    
    
    
21. ABBASI J
    Do All Patients Need beta-Blockers After a Heart Attack?
    JAMA. 2018;319:853-855.
    PubMed     Text format    
    
    
    February 2018
22. HUFFMAN MD, Mohanan PP, Devarajan R, Baldridge AS, et al
    Effect of a Quality Improvement Intervention on Clinical Outcomes in Patients in India With Acute Myocardial Infarction: The ACS QUIK Randomized Clinical Trial.
    JAMA. 2018;319:567-578.
    PubMed     Text format     Abstract available
    
    
    January 2018
23. WADHERA RK, Yeh RW, Joynt Maddox KE
    The Rise and Fall of Mandatory Cardiac Bundled Payments.
    JAMA. 2018;319:335-336.
    PubMed     Text format    
    
    
    
24. KENNEDY AB, Lavie CJ, Blair SN
    Fitness or Fatness: Which Is More Important?
    JAMA. 2018;319:231-232.
    PubMed     Text format    
    
    
    December 2017
25. GREENLAND P
    Cardiovascular Guideline Skepticism vs Lifestyle Realism?
    JAMA. 2017 Dec 14. pii: 2666625. doi: 10.1001/jama.2017.19675.
    PubMed     Text format    
    
    
    November 2017
26. SLOMSKI A
    Evolocumab Reduces Cardiovascular Risk Regardless of Diabetes Status.
    JAMA. 2017;318:1968.
    PubMed     Text format    
    
    
    
27. EMDIN CA, Khera AV, Kathiresan S
    Mendelian Randomization.
    JAMA. 2017;318:1925-1926.
    PubMed     Text format    
    
    
    
28. IRONY TZ
    The "Utility" in Composite Outcome Measures: Measuring What Is Important to Patients.
    JAMA. 2017;318:1820-1821.
    PubMed     Text format    
    
    
    
29. CHAPMAN AR, Lee KK, McAllister DA, Cullen L, et al
    Association of High-Sensitivity Cardiac Troponin I Concentration With Cardiac Outcomes in Patients With Suspected Acute Coronary Syndrome.
    JAMA. 2017 Nov 11. doi: 10.1001/jama.2017.17488.
    PubMed     Text format     Abstract available
    
    
    October 2017
30. ABBASI J
    Could a New Method to Detect Coronary Inflammation Prevent Heart Attacks?
    JAMA. 2017;318:1527-1528.
    PubMed     Text format    
    
    
    September 2017
31. WADHERA RK, Bhatt DL
    Taking the "Public" Out of Public Reporting of Percutaneous Coronary Intervention.
    JAMA. 2017 Sep 28. doi: 10.1001/jama.2017.12087.
    PubMed     Text format    
    
    
    
32. LICHTMAN JH, Jones MR, Leifheit EC, Sheffet AJ, et al
    Carotid Endarterectomy and Carotid Artery Stenting in the US Medicare Population, 1999-2014.
    JAMA. 2017;318:1035-1046.
    PubMed     Text format     Abstract available
    
    
    
33. BARNARD ND, Willett WC, Ding EL
    The Misuse of Meta-analysis in Nutrition Research.
    JAMA. 2017 Sep 18. doi: 10.1001/jama.2017.12083.
    PubMed     Text format    
    
    
    
34. DEVEREAUX PJ, Biccard BM, Chan MTV
    High-Sensitivity Troponin Levels, Ischemia, and Mortality-Reply.
    JAMA. 2017;318:865.
    PubMed     Text format    
    
    
    
35. SMILOWITZ NR
    High-Sensitivity Troponin Levels, Ischemia, and Mortality.
    JAMA. 2017;318:864-865.
    PubMed     Text format    
    
    
    August 2017
36. FERENCE BA, Kastelein JJP, Ginsberg HN, Chapman MJ, et al
    Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk.
    JAMA. 2017 Aug 28. doi: 10.1001/jama.2017.11467.
    PubMed     Text format     Abstract available
    
    
    
37. FELKER GM, Anstrom KJ, Adams KF, Ezekowitz JA, et al
    Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
    JAMA. 2017;318:713-720.
    PubMed     Text format     Abstract available
    
    
    
38. CHOLLEY B, Caruba T, Grosjean S, Amour J, et al
    Effect of Levosimendan on Low Cardiac Output Syndrome in Patients With Low Ejection Fraction Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass: The LICORN Randomized Clinical Trial.
    JAMA. 2017;318:548-556.
    PubMed     Text format     Abstract available
    
    
    
39. KRUMHOLZ HM
    Treatment of Cholesterol in 2017.
    JAMA. 2017;318:417-418.
    PubMed     Text format    
    
    
    July 2017
40. LARSSON SC, Burgess S, Michaelsson K
    Association of Genetic Variants Related to Serum Calcium Levels With Coronary Artery Disease and Myocardial Infarction.
    JAMA. 2017;318:371-380.
    PubMed     Text format     Abstract available
    
    
    
41. IOANNIDIS JPA
    Inconsistent Guideline Recommendations for Cardiovascular Prevention and the Debate About Zeroing in on and Zeroing LDL-C Levels With PCSK9 Inhibitors.
    JAMA. 2017 Jul 24. doi: 10.1001/jama.2017.6765.
    PubMed     Text format    
    
    
    
42. DHARMARAJAN K, Wang Y, Lin Z, Normand ST, et al
    Association of Changing Hospital Readmission Rates With Mortality Rates After Hospital Discharge.
    JAMA. 2017;318:270-278.
    PubMed     Text format     Abstract available
    
    
    
43. GROSSMAN DC, Bibbins-Domingo K, Curry SJ, Barry MJ, et al
    Behavioral Counseling to Promote a Healthful Diet and Physical Activity for Cardiovascular Disease Prevention in Adults Without Cardiovascular Risk Factors: US Preventive Services Task Force Recommendation Statement.
    JAMA. 2017;318:167-174.
    PubMed     Text format     Abstract available
    
    
    
44. PATNODE CD, Evans CV, Senger CA, Redmond N, et al
    Behavioral Counseling to Promote a Healthful Diet and Physical Activity for Cardiovascular Disease Prevention in Adults Without Known Cardiovascular Disease Risk Factors: Updated Evidence Report and Systematic Review for the US Preventive Services Tas
    JAMA. 2017;318:175-193.
    PubMed     Text format     Abstract available
    
    
    
45. JIN J
    Counseling on Healthy Living to Prevent Cardiovascular Disease in Adults Without Risk Factors.
    JAMA. 2017;318:210.
    PubMed     Text format    
    
    
    
46. YU J, Zhou Z, McEvoy RD, Anderson CS, et al
    Association of Positive Airway Pressure With Cardiovascular Events and Death in Adults With Sleep Apnea: A Systematic Review and Meta-analysis.
    JAMA. 2017;318:156-166.
    PubMed     Text format     Abstract available
    
    
    
47. GOTTLIEB DJ
    Does Obstructive Sleep Apnea Treatment Reduce Cardiovascular Risk?: It Is Far Too Soon to Say.
    JAMA. 2017;318:128-130.
    PubMed     Text format    
    
    
    
48. GREENLAND P, Fuster V
    Cardiovascular Risk Factor Control for All.
    JAMA. 2017;318:130-131.
    PubMed     Text format    
    
    
    June 2017
49. BUDOFF MJ, Ellenberg SS, Snyder PJ
    Changes in Coronary Artery Plaque With Testosterone Therapy-Reply.
    JAMA. 2017;317:2451.
    PubMed     Text format    
    
    
    
50. DHINDSA S, Wilson MF, Dandona P
    Changes in Coronary Artery Plaque With Testosterone Therapy.
    JAMA. 2017;317:2450.
    PubMed     Text format    
    
    
    
51. NAVATHE AS, Song Z, Emanuel EJ
    The Next Generation of Episode-Based Payments.
    JAMA. 2017;317:2371-2372.
    PubMed     Text format    
    
    
    
52. CHILDERS CP, Maggard-Gibbons M, Shekelle PG
    Antiplatelet Therapy in Patients With Coronary Stents Undergoing Elective Noncardiac Surgery: Continue, Stop, or Something in Between?
    JAMA. 2017 Jun 19. doi: 10.1001/jama.2017.7845.
    PubMed     Text format    
    
    
    May 2017
53. SLOMSKI A
    Redefining Acute Coronary Syndrome Therapy.
    JAMA. 2017;317:2054.
    PubMed     Text format    
    
    
    
54. ROTH GA, Dwyer-Lindgren L, Bertozzi-Villa A, Stubbs RW, et al
    Trends and Patterns of Geographic Variation in Cardiovascular Mortality Among US Counties, 1980-2014.
    JAMA. 2017;317:1976-1992.
    PubMed     Text format     Abstract available
    
    
    
55. MENSAH GA, Goff DC, Gibbons GH
    Cardiovascular Mortality Differences-Place Matters.
    JAMA. 2017;317:1955-1957.
    PubMed     Text format    
    
    
    April 2017
56. NICHOLLS SJ, Somaratne R, Nissen SE
    Evolocumab Added to Statins to Reduce Progression of Coronary Atherosclerosis-Reply.
    JAMA. 2017;317:1691.
    PubMed     Text format    
    
    
    
57. ALKHALIL M, Choudhury RP
    Evolocumab Added to Statins to Reduce Progression of Coronary Atherosclerosis.
    JAMA. 2017;317:1690-1691.
    PubMed     Text format    
    
    
    
58. MURRAY SW
    Evolocumab Added to Statins to Reduce Progression of Coronary Atherosclerosis.
    JAMA. 2017;317:1690.
    PubMed     Text format    
    
    
    
59. DEVEREAUX PJ, Biccard BM, Sigamani A, Xavier D, et al
    Association of Postoperative High-Sensitivity Troponin Levels With Myocardial Injury and 30-Day Mortality Among Patients Undergoing Noncardiac Surgery.
    JAMA. 2017;317:1642-1651.
    PubMed     Text format     Abstract available
    
    
    
60. SCHWARTZ MLB, Williams MS, Murray MF
    Adding Protective Genetic Variants to Clinical Reporting of Genomic Screening Results: Restoring Balance.
    JAMA. 2017;317:1527-1528.
    PubMed     Text format    
    
    
    March 2017
61. KHERA AV, Won HH, Peloso GM, O'Dushlaine C, et al
    Association of Rare and Common Variation in the Lipoprotein Lipase Gene With Coronary Artery Disease.
    JAMA. 2017;317:937-946.
    PubMed     Text format     Abstract available
    
    
    February 2017
62. BUDOFF MJ, Ellenberg SS, Lewis CE, Mohler ER 3rd, et al
    Testosterone Treatment and Coronary Artery Plaque Volume in Older Men With Low Testosterone.
    JAMA. 2017;317:708-716.
    PubMed     Text format     Abstract available
    
    
    
63. AGORITSAS T, Merglen A, Shah ND, O'Donnell M, et al
    Adjusted Analyses in Studies Addressing Therapy and Harm: Users' Guides to the Medical Literature.
    JAMA. 2017;317:748-759.
    PubMed     Text format     Abstract available
    
    
    
64. BILECEN S, de Groot JA, Kalkman CJ, Spanjersberg AJ, et al
    Effect of Fibrinogen Concentrate on Intraoperative Blood Loss Among Patients With Intraoperative Bleeding During High-Risk Cardiac Surgery: A Randomized Clinical Trial.
    JAMA. 2017;317:738-747.
    PubMed     Text format     Abstract available
    
    
    
65. EMDIN CA, Khera AV, Natarajan P, Klarin D, et al
    Genetic Association of Waist-to-Hip Ratio With Cardiometabolic Traits, Type 2 Diabetes, and Coronary Heart Disease.
    JAMA. 2017;317:626-634.
    PubMed     Text format     Abstract available
    
    
    January 2017
66. SILVERMAN MG, Im K, Sabatine MS
    Interventions to Lower Low-Density Lipoprotein Cholesterol and Cardiovascular Risk-Reply.
    JAMA. 2017;317:440.
    PubMed     Text format    
    
    
    
67. ZAFAR K, Inayat M
    Interventions to Lower Low-Density Lipoprotein Cholesterol and Cardiovascular Risk.
    JAMA. 2017;317:439-440.
    PubMed     Text format    
    
    
    
68. NAVARESE EP, Kolodziejczak M, De Servi S
    Interventions to Lower Low-Density Lipoprotein Cholesterol and Cardiovascular Risk.
    JAMA. 2017;317:439.
    PubMed     Text format    
    
    
    
69. BRAGG F, Holmes MV, Iona A, Guo Y, et al
    Association Between Diabetes and Cause-Specific Mortality in Rural and Urban Areas of China.
    JAMA. 2017;317:280-289.
    PubMed     Text format     Abstract available
    
    
    
70. GREENWOOD JP, Brown JM, Berry C
    Alternatives in the Evaluation of Suspected Coronary Heart Disease-Reply.
    JAMA. 2017;317:212-213.
    PubMed     Text format    
    
    
    
71. SCHWITTER J
    Alternatives in the Evaluation of Suspected Coronary Heart Disease.
    JAMA. 2017;317:211-212.
    PubMed     Text format    
    
    
    
72. BITTENCOURT MS, Fernandes JL
    Alternatives in the Evaluation of Suspected Coronary Heart Disease.
    JAMA. 2017;317:211.
    PubMed     Text format    
    
    
    
73. FOROUZANFAR MH, Liu P, Roth GA, Ng M, et al
    Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015.
    JAMA. 2017;317:165-182.
    PubMed     Text format     Abstract available
    
    
    December 2016
74. SLOMSKI A
    Celecoxib Similar to 2 NSAIDs for Cardiovascular Safety.
    JAMA. 2016;316:2589.
    PubMed     Text format    
    
    
    
75. DESAI NR, Ross JS, Kwon JY, Herrin J, et al
    Association Between Hospital Penalty Status Under the Hospital Readmission Reduction Program and Readmission Rates for Target and Nontarget Conditions.
    JAMA. 2016;316:2647-2656.
    PubMed     Text format     Abstract available
    
    
    
76. MORA S, Manson JE
    Shared Decision Making Regarding Aspirin in Primary Prevention of Cardiovascular Disease-Reply.
    JAMA. 2016;316:2276-2277.
    PubMed     Text format    
    
    
    
77. STOVITZ SD, Satin DJ, Shrier I
    Shared Decision Making Regarding Aspirin in Primary Prevention of Cardiovascular Disease.
    JAMA. 2016;316:2276.
    PubMed     Text format    
    
    
    November 2016
78. NICHOLLS SJ, Puri R, Anderson T, Ballantyne CM, et al
    Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.
    JAMA. 2016 Nov 15. doi: 10.1001/jama.2016.16951.
    PubMed     Text format     Abstract available
    
    
    
79. NAVAR AM, Peterson ED, Wojdyla D, Sanchez RJ, et al
    Temporal Changes in the Association Between Modifiable Risk Factors and Coronary Heart Disease Incidence.
    JAMA. 2016;316:2041-2043.
    PubMed     Text format    
    
    
    
80. KAVOUSI M, Desai CS, Ayers C, Blumenthal RS, et al
    Prevalence and Prognostic Implications of Coronary Artery Calcification in Low-Risk Women: A Meta-analysis.
    JAMA. 2016 Nov 15. doi: 10.1001/jama.2016.17020.
    PubMed     Text format     Abstract available
    
    
    
81. RODRIGUEZ F, Harrington RA
    Cholesterol, Cardiovascular Risk, Statins, PCSK9 Inhibitors, and the Future of LDL-C Lowering.
    JAMA. 2016;316:1967-1968.
    PubMed     Text format    
    
    
    
82. BIBBINS-DOMINGO K, Grossman DC, Curry SJ, Davidson KW, et al
    Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement.
    JAMA. 2016;316:1997-2007.
    PubMed     Text format     Abstract available
    
    
    
83. CHOU R, Dana T, Blazina I, Daeges M, et al
    Statins for Prevention of Cardiovascular Disease in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force.
    JAMA. 2016;316:2008-2024.
    PubMed     Text format     Abstract available
    
    
    
84. SONG Z, Blumenthal DM
    Expanding Payment Reform in Medicare: The Cardiology Episode-Based Payment Model.
    JAMA. 2016;316:1973-1974.
    PubMed     Text format    
    
    
    
85. ABBASI J
    Do Apollo Astronaut Deaths Shine a Light on Deep Space Radiation and Cardiovascular Disease?
    JAMA. 2016 Nov 9. doi: 10.1001/jama.2016.12601.
    PubMed     Text format    
    
    
    
86. LEGATO MJ, Johnson PA, Manson JE
    Consideration of Sex Differences in Medicine to Improve Health Care and Patient Outcomes.
    JAMA. 2016;316:1865-1866.
    PubMed     Text format    
    
    
    October 2016
87. HAMPTON T
    Reservoir of Genetic Data Related to Cardiovascular Disease.
    JAMA. 2016;316:1349.
    PubMed     Text format    
    
    
    
88. LOTTA LA, Sharp SJ, Burgess S, Perry JR, et al
    Association Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes: A Meta-analysis.
    JAMA. 2016;316:1383-1391.
    PubMed     Text format     Abstract available
    
    
    September 2016
89. SILVERMAN MG, Ference BA, Im K, Wiviott SD, et al
    Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis.
    JAMA. 2016;316:1289-97.
    PubMed     Text format     Abstract available
    
    
    
90. MILLS K, He J
    Sodium Excretion, Cardiovascular Disease, and Chronic Kidney Disease.
    JAMA. 2016;316:1112-3.
    PubMed     Text format    
    
    
    
91. ALMIRALL J
    Sodium Excretion, Cardiovascular Disease, and Chronic Kidney Disease.
    JAMA. 2016;316:1112.
    PubMed     Text format    
    
    
    
92. HURSITOGLU M
    Sodium Excretion, Cardiovascular Disease, and Chronic Kidney Disease.
    JAMA. 2016;316:1112.
    PubMed     Text format    
    
    
    
93. HEMKENS LG, Ewald H, Briel M
    Colchicine and Prevention of Cardiovascular Events.
    JAMA. 2016;316:1106-7.
    PubMed     Text format     Abstract available
    
    
    August 2016
94. HALL M, Dondo TB, Yan AT, Goodman SG, et al
    Association of Clinical Factors and Therapeutic Strategies With Improvements in Survival Following Non-ST-Elevation Myocardial Infarction, 2003-2013.
    JAMA. 2016 Aug 30. doi: 10.1001/jama.2016.10766.
    PubMed     Text format     Abstract available
    
    
    
95. BOHULA EA, Antman EM
    Management of Non-ST-Elevation Myocardial Infarction: The Bright Gleam of Progress, But Much Work Remains.
    JAMA. 2016 Aug 30. doi: 10.1001/jama.2016.11940.
    PubMed     Text format    
    
    
    
96. GREENWOOD JP, Ripley DP, Berry C, McCann GP, et al
    Effect of Care Guided by Cardiovascular Magnetic Resonance, Myocardial Perfusion Scintigraphy, or NICE Guidelines on Subsequent Unnecessary Angiography Rates: The CE-MARC 2 Randomized Clinical Trial.
    JAMA. 2016 Aug 29. doi: 10.1001/jama.2016.12680.
    PubMed     Text format     Abstract available
    
    
    
97. KAZI DS, Moran AE, Coxson PG, Penko J, et al
    Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
    JAMA. 2016;316:743-53.
    PubMed     Text format     Abstract available
    
    
    
98. LIVINGSTON EH
    JAMA PATIENT PAGE. Screening for Lipid Disorders in Children and Adolescents.
    JAMA. 2016;316:678.
    PubMed     Text format    
    
    
    
99. LOZANO P, Henrikson NB, Dunn J, Morrison CC, et al
    Lipid Screening in Childhood and Adolescence for Detection of Familial Hypercholesterolemia: Evidence Report and Systematic Review for the US Preventive Services Task Force.
    JAMA. 2016;316:645-55.
    PubMed     Text format     Abstract available
    
    
    
100. LOZANO P, Henrikson NB, Morrison CC, Dunn J, et al
     Lipid Screening in Childhood and Adolescence for Detection of Multifactorial Dyslipidemia: Evidence Report and Systematic Review for the US Preventive Services Task Force.
     JAMA. 2016;316:634-44.
     PubMed     Text format     Abstract available
     
     
     July 2016
101. NUTI SV, Qin L, Krumholz HM
     Outcome After Admission at Veterans Affairs vs Non-Veterans Affairs Hospitals--Reply.
     JAMA. 2016;316:346.
     PubMed     Text format    
     
     
     
102. RADOMSKI TR, Fine MJ, Gellad WF
     Outcome After Admission at Veterans Affairs vs Non-Veterans Affairs Hospitals.
     JAMA. 2016;316:345-6.
     PubMed     Text format    
     
     
     June 2016
103. CHOBANIAN AV
     SPRINT Results in Older Patients: How Low to Go?
     JAMA. 2016;315:2669-70.
     PubMed     Text format    
     
     
     
104. GANZ P, Heidecker B, Hveem K, Jonasson C, et al
     Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients With Stable Coronary Heart Disease.
     JAMA. 2016;315:2532-41.
     PubMed     Text format     Abstract available
     
     
     
105. SABATINE MS
     Using Aptamer-Based Technology to Probe the Plasma Proteome for Cardiovascular Disease Prediction.
     JAMA. 2016;315:2525-6.
     PubMed     Text format    
     
     
     
106. MORA S, Ames JM, Manson JE
     Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease: Shared Decision Making in Clinical Practice.
     JAMA. 2016 Jun 20. doi: 10.1001/jama.2016.8362.
     PubMed     Text format    
     
     
     
107. HONG SJ, Kim BK, Hong MK
     Ultrasound vs Angiography for Drug-Eluting Stent Implantation--Reply.
     JAMA. 2016;315:2469-70.
     PubMed     Text format    
     
     
     
108. STEINVIL A, Waksman R, Garcia-Garcia HM
     Ultrasound vs Angiography for Drug-Eluting Stent Implantation.
     JAMA. 2016;315:2469.
     PubMed     Text format    
     
     
     
109. TUNCEZ A, Altunkeser BB
     Ultrasound vs Angiography for Drug-Eluting Stent Implantation.
     JAMA. 2016;315:2468-9.
     PubMed     Text format    
     
     
     
110. HOFFER EK
     Ultrasound vs Angiography for Drug-Eluting Stent Implantation.
     JAMA. 2016;315:2468.
     PubMed     Text format    
     
     
     
111. MANSON JE, Shufelt CL, Robins JM
     The Potential for Postrandomization Confounding in Randomized Clinical Trials.
     JAMA. 2016;315:2273-4.
     PubMed     Text format    
     
     
     May 2016
112. MILLS KT, Chen J, Yang W, Appel LJ, et al
     Sodium Excretion and the Risk of Cardiovascular Disease in Patients With Chronic Kidney Disease.
     JAMA. 2016;315:2200-10.
     PubMed     Text format     Abstract available
     
     
     
113. POWE NR, Bibbins-Domingo K
     Dietary Salt, Kidney Disease, and Cardiovascular Health.
     JAMA. 2016;315:2173-4.
     PubMed     Text format    
     
     
     
114. WILLIAMSON JD, Supiano MA, Applegate WB, Berlowitz DR, et al
     Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged >/=75 Years: A Randomized Clinical Trial.
     JAMA. 2016 May 19. doi: 10.1001/jama.2016.7050.
     PubMed     Text format     Abstract available
     
     
     April 2016
115. PENCINA MJ, Peterson ED
     Moving From Clinical Trials to Precision Medicine: The Role for Predictive Modeling.
     JAMA. 2016;315:1713-4.
     PubMed     Text format    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Ischemic Heart Disease is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: